Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
The rationale and design of the AASK cohort study.
Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. Appel LJ, et al. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S166-72. doi: 10.1097/01.asn.0000070081.15137.c0. J Am Soc Nephrol. 2003. PMID: 12819323
The role of calcium antagonists in chronic kidney disease.
Gashti CN, Bakris GL. Gashti CN, et al. Among authors: bakris gl. Curr Opin Nephrol Hypertens. 2004 Mar;13(2):155-61. doi: 10.1097/00041552-200403000-00003. Curr Opin Nephrol Hypertens. 2004. PMID: 15202609 Review.
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA. Jamerson KA, et al. Among authors: bakris gl. Am J Hypertens. 2004 Sep;17(9):793-801. doi: 10.1016/j.amjhyper.2004.05.004. Am J Hypertens. 2004. PMID: 15363822 Review.
846 results